The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab.

Magnes, T, Melchardt, T, Hufnagl, C, Weiss, L, Mittermair, C, Neureiter, D, Klieser, E, Rinnerthaler, G, Roesch, S, Gaggl, A, Greil, R, Egle, A.

http://www.ncbi.nlm.nih.gov/pubmed/28719596